Clinical Guidelines Publication

Home / News & Publications / Official Release: Saudi National Guidelines for Prostate Cancer
Clinical Guidelines Release Official Guideline Release Full Version Available Peer-Reviewed Consensus

Official Release: Saudi National Guidelines for Prostate Cancer

The multidisciplinary expert steering committee of the Saudi Genitourinary (GU) Working Group has officially published the comprehensive clinical practice guidelines. This evidence-based document provides standardized diagnostic algorithms, risk stratification matrices, and localized systemic sequencing pathways for healthcare providers across Saudi Arabia.
Official Release: Saudi National Guidelines for Prostate Cancer
Official cover and multidisciplinary framework published by the Saudi GU Working Group committee.

Executive Overview & Clinical Impact

Genitourinary oncologists and urologic surgeons in Saudi Arabia now have direct access to an updated, unified national reference framework. These guidelines synthesize the latest global evidence (including EAU, ESMO, and ASCO consensus) and tailor diagnostic and therapeutic algorithms to the specific healthcare capabilities and formulary pathways of the Kingdom.

Key Chapters & Clinical Modules Included

The full online guideline platform features interactive decision trees, high-resolution diagnostic charts, and evidence grades across each phase of disease:

Module 01

Early Detection, PSA Screening & mpMRI Biopsy

Age-tailored PSA thresholds, risk calculators, PIRADS classification, and MRI/transrectal ultrasound fusion biopsy pathways.
Module 02

Localized Disease Risk Group Stratification

Differentiating very low, low, intermediate, and high-risk prostate adenocarcinoma to guide active surveillance vs. definitive therapy.
Module 03

Radiation Therapy & Androgen Deprivation Synergy

Dose-escalated radiotherapy, stereotactic body radiotherapy (SBRT), and short- vs. long-course ADT intensification.
Module 04

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Systemic treatment intensification utilizing doublet and triplet therapies (ADT + ARPI ± Docetaxel) based on volume criteria.
Module 05

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sequencing ARPIs, taxane chemotherapies, PARP inhibitors for HRR alterations, and PSMA-targeted radioligand theranostics (177Lu-PSMA-617).

Access the Complete Interactive Prostate Cancer Guidelines

Review all 14+ clinical decision algorithms, evidence citations, staging nomograms, and treatment protocols on our specialized guideline platform.

Explore Complete Prostate Cancer Guidelines →